The company decided to expand its operations following increased demand for its Vertical Auto Profile (VAP) advanced cholesterol test and other clinical laboratory services.

Atherotech’s patented VAP Test measures cholesterol markers associated with heart disease and reports the cholesterol content of all lipids, components and subclasses.

The company also provides its testing services to physicians, hospitals, clinics and other laboratories.

Atherotech CEO Michael Mullen said this expansion reflects the success of their growth strategy and is supported by strong sales of their VAP Test and the addition of new diagnostic testing capabilities.